American CryoStem Corporation (OTCQB: CRYO), a leading biotech company in the field of Regenerative Medicine, today announced that the Company will be featuring Personal Cell Sciences and the Company’s ATGRAFT™ platform at the upcoming St. Armand Ventures Experience, themed “Face Your Future,” to be held in New York City, April 9, 2013, from 6:00PM – 10:00PM, at Newel, a decorative and fine arts gallery, serving its clientele for over 70 years.
Brought to you by St. Armand Ventures, this private, invitation-only, high impact, ticketed, networking event takes place only twice a year in New York City to facilitate connectivity among global, conscious trailblazers in a wide range of fields from banking, real estate, wall street, life sciences, film, insurance, art, technology, culture, entrepreneurship and more.
EVENT AT A GLANCE
WHO: John Arnone – Chairman and CEO
Anthony Dudzinski – COO
WHEN: Tuesday, April 9, 2013
6:00PM ET – 10:00 PM ET
WHERE: Newel New York
425 East 53rd Street
New York, New York
About St. Armand Ventures
The St. Armand Ventures (SAV) Experience brings you remarkable consulting experiences and meaningful business opportunities year round. At the St. Armand Ventures Experiences we enjoy a great evening out which you will remember for a long time to come. The SAV Experiences events usually take place twice a year, and have been hosted for eight years. Our motto is AienAristeuein – Ever to Excel. We are engaged in unique, cutting edge, future forward business pursuits and invite you to present your projects, ideas or inquiries to us. For more information, visit www.saintarmandventures.com.
About American CryoStem Corporation
A pioneer in the fields of Regenerative and Personalized Medicine, American CryoStem is a developer, marketer and global licensor of patented adipose tissue based cellular technologies and related proprietary services with a focus on clinical processing, commercial bio-banking and application development for adipose (fat) tissue and autologous adipose-derived regenerative cells (ADRCs). The Company maintains a strategic portfolio of intellectual property and patent applications that form its Adipose Tissue Processing Platform, which supports and promotes a growing pipeline of biologic products and processes, clinical services and international licensing opportunities. Through its ACS Laboratories division, the Company operates an FDA registered, cGMP compliant human tissue processing, cryo-storage and cell culture and differentiation media development facility in Mount Laurel, New Jersey. For more information, please visit www.americancryostem.com and www.acslaboratories.com.